Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

Mayne Pharma Agrees AU$604 Million Takeover by Gedeon Richter at AU$6.40 a Share

Mayne Pharma Agrees AU$604 Million Takeover by Gedeon Richter at AU$6.40 a Share Source: Kapitales Research

Highlights:

  • Gedeon Richter will acquire Mayne Pharma through a scheme of arrangement at AU$6.40 per share in cash.

  • The price values the equity at about AU$604 million, a 99.4% premium to the 16 November 2026 closing price.

  • The board unanimously recommends the deal, and a vote is expected in late January 2027.

The Deal in Brief

On 17 November 2026, Mayne Pharma Group Limited (ASX: MYX) announced a scheme implementation deed with Hungary-based Gedeon Richter Plc. Richter will buy all of the company’s shares for AU$6.40 each in cash, valuing the equity at roughly AU$604 million. The offer is fully funded from Richter’s internal cash, with no financing condition. Mayne Pharma shares last traded at AU$5.750, up 79.127%, still below the AU$6.40 offer price.

A Substantial Premium

The price sits 99.4% above the previous close and well above longer-term averages, with premiums of 124% to the 30-day VWAP, 122% to the 90-day VWAP and 145% to the 180-day VWAP.

Board and Shareholder Support

Directors unanimously recommend the scheme, provided no superior proposal emerges and the independent expert concludes it is in shareholders’ best interests. The three largest holders, Funicular Funds (9.82%), Bruce Mathieson (6.46%) and Trium Capital (5.85%), together own 22.14% and intend to vote in favour.

Conditions and Timetable

The scheme needs approval from regulators, including the Foreign Investment Review Board and under United States antitrust law, plus shareholder and court approval. The parties will also file a voluntary declaration with the US foreign investment committee, CFIUS. A further condition is the completion of Mayne’s sale of its International business to Evaris Pharma, announced on 6 November 2026. A scheme booklet is due in mid-December, the shareholder meeting is expected in late January 2027, and implementation is targeted for mid to late March 2027.

Convertible Notes

Convertible notes held by Rubric Capital mature on 31 December 2026. If converted at AU$5.356 per share, Rubric would receive 7,685,488 shares that would take part in the scheme.

What Shareholders Should Do

No action is needed yet. Until the scheme completes, the company says it is business as usual. Shareholders should read the scheme booklet and independent expert’s report when they arrive.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au